Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation
Open Access
- 1 July 2017
- journal article
- research article
- Published by Elsevier in The Lancet Global Health
- Vol. 5 (7) , e710-e719
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?The Lancet Infectious Diseases, 2014
- Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countriesBulletin of the World Health Organization, 2014
- Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trialThe Lancet, 2014
- New diagnostic test changes tuberculosis landscapeBulletin of the World Health Organization, 2013
- Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010The Lancet, 2012
- Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic EvaluationPLOS Medicine, 2012
- METHODS FOR COVARIATE ADJUSTMENT IN COST‐EFFECTIVENESS ANALYSIS THAT USE CLUSTER RANDOMISED TRIALSHealth Economics, 2012
- COST‐MINIMISATION ANALYSIS VERSUS COST‐EFFECTIVENESS ANALYSIS, REVISITEDHealth Economics, 2011
- Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness AnalysisPLOS Medicine, 2011
- Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized TrialsMedical Decision Making, 2011